相关实验视频
Updated: Jul 13, 2026

08:50
Stabilizing Hepatocellular Phenotype Using Optimized Synthetic Surfaces
Published on: September 26, 2014
准备,表征和基质新陈代谢黄金固定化细胞染色体P450 2C9的基质新陈代谢
Peter M Gannett1, Jarod Kabulski, Felio A Perez
1Basic Pharmaceutical Sciences, West Virginia University, P.O. Box 9530, Morgantown, WV 26506, USA. pgannett@hsc.wvu.edu
Journal of the American Chemical Society
|June 29, 2006
概括
研究人员开发了一种新方法,可以在黄金表面上固定P450 2C9 (CYP2C9) 细胞染色体. 这一突破使得研究酶相互作用和代谢能够用于制药应用.
科学领域:
- 生物化学和分子生物学
- 纳米技术和表面科学研究
- 酶工程和固定化工程
背景情况:
- 细胞染色体P450酶是重要的含血蛋白,在新陈代谢中起着重要的作用.
- 在表面上固定P450酶对研究酶动力学,相互作用和开发生物传感器非常感兴趣.
- 以前的固定化策略通常涉及将酶嵌入矩阵或表面,成功程度各不相同.
研究的目的:
- 开发一种用于将细胞染色体P450 2C9 (CYP2C9) 酶连接到黄金基质的新方法.
- 创建功能化的酶结构,能够结合和代谢基质.
- 为潜在的生物传感器应用在表面上建立可测量的CYP2C9代谢活性条件.
主要方法:
- 使用特定的链接分子将CYP2C9附着在黄金基质上.
- 使用超导量子干扰装置 (SQUID) 磁力测量来监测基质与酶的结合.
- 优化酶附着和辅因子存在 (NADPH和细胞染色体P450减少酶) 的条件,以确保活性.
主要成果:
- 在黄金基板上成功固定CYP2C9,保持其结合和代谢基板的能力.
- 证明酶活性取决于链接选择和固定过程中必需的辅助因子的存在.
- 已形成条件,可以在功能化黄金表面上测量CYP2C9代谢活性.
结论:
- 已经建立了一种用于固定CYP2C9在黄金表面的新方法,保持酶功能.
- 开发的系统允许使用SQUID磁力测量来研究基质-酶相互作用.
- 这项工作为为药物代谢查和理解酶行为的生物传感器的创建提供了基础.
相关概念视频
Drug Metabolism: Phase I Reactions
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Jaundice
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...

